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SUMMARY - Hypertrophic cardiomyopathy is a primary cardiac muscle disease with clinical mani-
festations that vary from a benign asymptomatic course to severe heart failure or cardiac arrest. There-
fore, the identification of individual risk of sudden cardiac death is the first step in the treatment of
patients with hypertrophic cardiomyopathy. The factors that best identify high risk patients include
a history of cardiac arrest or syncope, inducible sustained ventricular tachyarrhythmia, nonsustained
ventricular tachycardia in symptomatic patients, presence of ischemia associated with hypotension in
children, and presence of mutations in the beta-myosin heavy chain along with family history of
sudden cardiac death. The treatment of patients with hypertrophic cardiomyopathy depends on the
symptoms and risk degree. Patients with cardiac arrest, sustained ventricular tachycardia, or induc-
ible sustained ventricular tachyarrhythmia during programmed ventricular stimulation have an indi-
cation for implantable cardioverter-defibrillator. Patients with the symptoms of impaired conscious-
ness and nonsustained ventricular tachycardia without inducible sustained ventricular tachyarrhythmias
can be treated with amiodarone. Asymptomatic patients with nonsustained ventricular tachycardia
do not need prophylactic drug therapy, because their prognosis is the same as the prognosis of as-
ymptomatic patients without such tachycardia. Asymptomatic patients with two or more risk factors
are candidates for electrophysiological testing and subsequent pharmacological or nonpharmacological
therapy. On the other hand, asymptomatic patients free from risk factors have a good prognosis and
should be allowed to lead a normal life. However, in young asymptomatic patients or athletes, dis-
continuation of competitive, high- and medium-grade physical activity is mandatory, because this
measure significantly reduces their risk of sudden cardiac death.
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Introduction
Hypertrophic cardiomyopathy is a primary cardiac
muscle disease, which is defined by ventricular left and/
or right ventricular hypertrophy in the absence of any car-
diac or systemic cause1. Although the cause of hyper-
trophic cardiomyopathy is not completely known, a ma-
jority of cases are caused by mutation of the genes that
encode the proteins of the cardiac muscle sarcomere2.
Clinically, two forms of hypertrophic cardiomyopathy may
be distinguished: hypertrophic obstructive cardiomyopa-
thy characterized by the presence of a resting or provocable
gradient between the apex and the outflow tract in the left
ventricle, and hypertrophic nonobstructive cardiomyopa-
thy that has no intraventricular gradient at rest or on
provocation (Table 1)3. Recent studies have shown that the
prevalence of hypertrophic cardiomyopathy in the general
population is between 0.2% and 0.02%4,5. The clinical
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course of the disease is very variable. Many patients remain
asymptomatic and unaware of their disease for years, some
have cerebral symptoms on exertion, some have severe
symptoms of heart failure or ischemia, and some die sud-
denly, without previous symptoms. Therefore, continuing
efforts have been made in risk stratification and appropri-
ate therapy for these patients.
The Incidence of Sudden Cardiac Death in
Hypertrophic Cardiomyopathy
Sudden cardiac death is a significant cause of mortal-
ity in patients with hypertrophic cardiomyopathy, but its
incidence depends on the study population (Table 2).
Earlier hospital-based clinical investigations have reported
on the annual incidence of sudden death of 2% to 4% in
adults, and 4% to 6% in children and adolescents8. In re-
cent outpatient and regionally selected population stud-
ies, the annual risk of cardiac mortality is about 1% (0.7%
for sudden death), and hypertrophic cardiomyopathy does
not significantly affect the overall life expectancy9,10. It is
important to note that asymptomatic patients are at an
even lower annual risk of sudden death (0.1%)6.
The Mechanisms of Sudden Cardiac Death in
Hypertrophic Cardiomyopathy
There are many potential mechanisms of sudden car-
diac death in patients with hypertrophic cardiomyopa-
thy. A sudden onset of any supraventricular tachyarrhy-
thmia can be associated with severe hypotension, espe-
cially if there is a concurrent left ventricular outflow
obstruction, impaired diastolic function, or myocardial
ischemia. Atrial fibrillation, alone or associated with pre-
excitation syndrome, can induce highly devastating he-
modynamic sequels and precipitate sudden death due to
rapid heart rate, loss of atrial contribution to cardiac
output, and irregular filling and emptying of the left
ventricle. Acute myocardial ischemia or even myocardial
infarction is rarely the cause of sudden death, but they
can precipitate ventricular tachyarrhythmia causing car-
diac arrest. Complete heart block has also been reported
as a potential cause of sudden death, but it occurred in a
few cases only11.
The available data suggest that ventricular tachyarrhyt-
hmias are the cause of sudden death in most patients with
hypertrophic cardiomyopathy, either as a primary event
related to an arrhythmogenic substrate (disarray or myo-
cardial scarring) or as a secondary phenomenon triggered
by myocardial ischemia, diastolic dysfunction, outflow
obstruction, or supraventricular tachyarrhythmias12.
Evaluation of Patients at Risk
One of the main aims on assessing patients with hy-
pertrophic cardiomyopathy is the identification of indi-
vidual risk for sudden cardiac death. A number of identi-
fiable risk factors have been proposed: family history of
sudden death, exercise-induced hypotension, history of
syncope, nonsustained ventricular tachycardia on 24- or
48-hour Holter monitoring, and inducible ventricular ta-
chycardia or ventricular fibrillation (Table 3). In children






normal (supranormal) systolic function
impaired systolic function (end-stage hypertrophic
cardiomyopathy)
Table 2. Clinical presentation and prognosis (follow-up, 7-10 years)
Asymptomatic6 Symptomatic6 Cardiac arrest survivors7
(n=58) (n=70) (n=33)
Mean age (yrs) 42.8 50.4 32
Family history of hypertrophic cardiomyopathy 16% 7% 51%
Sudden death 2% 11% 24%
All-cause mortality 9% 24% 33%
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and adolescents, only the first three factors are used, know-
ing that syncope, rare though, carries a very poor progno-
sis. In older patients aged up to 40, all five factors are valid
for risk stratification. Unfortunately, all the risk factors
proposed have a low positive predictive value, because a
majority of patients with one of these factors will never
have sudden death. On the other hand, their negative pre-
dictive value for sudden death is very high. Therefore, a
patient with none of these factors has a favorable prognosis
and should be allowed to lead normal life. The risk is con-
sidered to be higher when two or three of the factors are
associated. In children and adolescents with hypertrophic
cardiomyopathy, syncope on exertion is an ominous symp-
tom, but the risk is higher when it occurs in individuals
with a family history of sudden cardiac death13. A similar
logic should be used in patients with hypertrophic cardi-
omyopathy who have nonsustained ventricular tachycar-
dia. In these patients, the risk of nonsustained ventricu-
lar tachycardia is significantly higher when tachycardia
occurs in combination with the symptoms of impaired
consciousness15. New possibilities in the risk stratification
have been offered by the finding that some gene muta-
tions, such as cardiac troponin T and beta cardiac myosin
heavy chain mutations causing hypertrophic cardiomyopa-
thy, indicate a particularly high risk of sudden cardiac
death16. However, this genetic stratification has not yet
become available in routine clinical practice.
Therapy to Prevent Sudden Cardiac Death
A number of factors limit our ability to effectively pre-
vent sudden cardiac death in an individual. These factors
include low prevalence of hypertrophic cardiomyopathy,
low incidence of death among affected patients, and a
variety of clinical conditions that may cause death. In one
of the largest groups of prospectively investigated hyper-
trophic cardiomyopathy patients, the loss of consciousness
was the only independent clinical predictor of future
events during follow-up15. Although the mortality rate in
this subgroup was still low (about 13% at 5 years), it seems
reasonable to assess the risk by subdividing the affected
patients into asymptomatic or mildly symptomatic pa-
tients and those with the symptoms of impaired con-
sciousness.
There is clinical consensus that an asymptomatic patient
without previously outlined clinical risk factors is at a low
risk of sudden cardiac death. Most adult patients with such
a profile can be reassured and do not require prophylactic
therapy, but should be reassessed at intervals, at least until
they have completed adolescent growth1. Recently, Corrado
et al.5 investigated the impact of disqualification from in-
tense physical activity on the future risk of sudden cardiac
death in patients with identified hypertrophic cardiomyopa-
thy. During the study period, the incidence of sudden death
was 1.6 per 100,000 per year among competitive athletes
and 0.75 per 100,000 per year among nonathletes aged (35.
Out of 337735 competitive athletes undergoing preparti-
cipation screening, 22 were found to have hypertrophic
cardiomyopathy and were disqualified from further physi-
cal activity. During the follow-up, hypertrophic cardiomy-
opathy caused only one (2%) sudden death among the ath-
letes, whereas in the nonathlete population it caused 16
(7.3%) sudden deaths. None of the 22 athtletes who were
disqualified from sports activities for hypertrophic cardi-
omyopathy died during the follow-up. These data support
the opinion that the identification and disqualification from
further physical activity of patients with asymptomatic or
mildly symptomatic hypertrophic cardiomyopathy may sig-
nificantly reduce their risk of sudden cardiac death.
Asymptomatic or mildly symptomatic patients with
hypertrophic cardiomyopathy and nonsustained ventricu-
lar tachycardia on ambulatory Holter have a low risk of
sudden cardiac death and the same prognosis as the pa-
tients with this disease without nonsustained ventricular
tachycardia15,17. Accordingly, episodes of nonsustained
Table 3. Hypertrophic cardiomyopathy - predictive value of risk factors for sudden cardiac death
Predictive accuracy
positive negative
Family history of sudden cardiac death13 28 88
Exercise-induced hypotension14 15 97
Syncope12 25 86
Nonsustained ventricular tachycardia8 22 97
Inducible ventricular tachycardia/ventricular fibrillation15 18 97
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ventricular tachycardia should not be considered an indi-
cation for prophylactic antiarrhythmic treatment in as-
ymptomatic patients.
In patients with symptoms of impaired consciousness,
the conventional risk factor stratification may identify the
subgroup of patients with hypertrophic cardiomyopathy
who are at an increased or high risk of sudden cardiac
death (Table 4). In approximately 30% of these patients,
a probable initiating mechanism that is amenable to spe-
cific therapy can be identified. Paroxysmal atrial fibrilla-
tion can be effectively prevented with amiodarone, rapid
atrioventricular conduction via an accessory pathway by
radiofrequency catheter ablation, ischemia with high dose
verapamil or beta-blockers, and left ventricular obstruc-
tion by dual chamber pacing or myectomy.
In other patients, who are considered to be at a par-
ticularly high risk of life-threatening tachyarrhythmias,
the available therapeutic options for prevention of sudden
cardiac death include amiodarone, implantable cardio-
verter defibrillator, or myectomy. amiodarone was given to 50 patients for the symptoms
refractory to conventional therapy, 21 of them with
nonsustained ventricular tachycardia on Holter monitor-
ing. Seven deaths were recorded during a mean follow-
up, six within 5 months of therapy initiation. Among 21
patients with nonsustained ventricular tachycardia prior
to amiodarone therapy, the survival rate at 2 years was only
62%. It should be noted that the dosage of amiodarone
used in this study was higher (loading dose of up to 1600
mg/day and maintenance dose of 400 mg/day) than usual,
and that the proarrhythmic action of amiodarone could
not be excluded in some cases. In a later study in 35 pa-
tients undergoing electrophysiological testing, amio-
darone was shown to facilitate ventricular tachycardia or
fibrillation induction in about 50% of patients with hy-
pertrophic cardiomyopathy20. This group of patients had
a significantly higher risk of arrhythmic events during
follow-up than the patients in whom ventricular tachy-
cardia was rendered noninducible or more difficult to in-
duce after amiodarone therapy. The data reported from
these studies show that amiodarone is not as effective in
hypertrophic cardiomyopathy as it was previously thought
to be, and that asymptomatic patients with nonsustained
ventricular tachycardia should not be administered amio-
darone as prophylactic therapy. However, in symptomatic
patients with nonsustained ventricular tachycardia, elec-
trophysiological testing of amiodarone should be per-
formed before starting prophylactic therapy with this
drug. In a recent study, Elliott et al. obtained some evi-
dence for the beneficial effect of amiodarone in patients
Table 4. Hypertrophic cardiomyopathy - patients at high risk of sud-
den cardiac death
° history of cardiac arrest or syncope
° episodes of sustained monomorphic or polymorphic
ventricular tachycardia
° induction of sustained ventricular tachycardia/ventricu-
lar fibrillation on electrophysiological testing
° nonsustained ventricular tachycardia associated with
presyncope or syncope
° myocardial ischemia associated with hypotension
° gene mutation associated with high incidence of sud-
den death
° severe left ventricular outflow obstruction
Antiarrhythmic Drug Therapy
To date, amiodarone is the only prophylactic drug
therapy that has been tested in high risk patients with-
out a history of sudden cardiac death (Table 5). McKenna
et al.18 report that patients treated with amiodarone for
nonsustained ventricular tachycardia had a more favorable
outcome on Holter than those treated with conventional
antiarrhythmics. The 3-year survival was 100% and 82%
for patients on amiodarone and those on conventional
therapy, respectively. In the study of Fananapazir et al.19,
Table 5. Hypertrophic cardiomyopathy - amiodarone in prevention




Ventricular tachycardia 21 0
Ventricular tachycardia -
disopyramide, mexiletine,
or quinidine 24 20
No ventricular tachycardia -




No ventricular tachycardia -
amiodarone 29  3
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at high risk21. They stratified 474 consecutive patients
according to the presence of one or no risk factor (low risk
group, n=284), or two or more risk factors (high risk
group, n=109). During the mean follow-up of 1121 days,
81 patients received amiodarone as monotherapy. In the
patients who did not receive amiodarone, the annual rate
of sudden death was 2.5% in the high risk group, and 1.3%
in the low risk group. None of the treated patients on
amiodarone died during the follow-up period. Therefore,
although unequivocal evidence in support of amiodarone
is lacking, the weight of evidence strongly favors the use
of amiodarone in high risk groups of patients.
Recently, Elliott et al. compared the efficacy of
amiodarone and implantable cardioverter-defibrillator
therapy in 16 patients with hypertrophic cardiomyopathy
who survived cardiac arrest22.The choice of treatment was
based on the failure of low dose amiodarone, availability
of appropriate devices, and individual patient preference.
Eight patients were on low dose amiodarone (200 to 300
mg), six patients underwent implantation of implantable
cardioverter-defibrillator, and two patients declined any
prophylactic therapy. During a mean follow-up of 6 years,
two patients died while taking amiodarone, and one pa-
tient died who had refused drug and device prevention.
Of six patients with implantable cardioverter-defibrilla-
tor, three had appropriate discharge for ventricular tachy-
cardia or ventricular fibrillation. In two patients, interro-
gation of the implantable cardioverter-defibrillator re-
vealed several episodes of atrial fibrillation degenerating
into polymorphic ventricular tachydardia and sinus tachy-
cardia followed by ventricular tachycardia. Although the
number of study patients was small, the authors conclude
that the patients with hypertrophic cardiomyopathy who
survive cardiac arrest should preferentially be treated with
implantable cardioverter-defibrillator.
Implantable Cardioverter-Defibrillator
There are only a few retrospective studies on the effi-
cacy of implantable cardioverter-defibrillator in patients
with hypertrophic cardiomyopathy, and the indications of
its use, especially for primary prevention, have not yet been
established. In a study of Silka et al.23, a cardioverter-
defibrillator was implanted in 44 patients (age <20 years)
with hypertrophic cardiomyopathy. The indications for
implantation included cardiac arrest in personal history,
drug-refractory ventricular tachycardia, and syncope with
inducible ventricular tachyarrhythmias. During a mean
follow-up of 31 months, the implantable cardioverter-
defibrillator had an appropriate discharge in 25 (57%)
patients. In a study of Tripodi et al.24, a cardioverter-
defibrillator was implanted in 31 patients with hyper-
trophic cardiomyopathy, and the rate of appropriate dis-
charge was 32% during a 33-month period. Borggreffe et
al.12 report on 14 patients with hypertrophic cardiomy-
opathy and implantable cardioverter-defibrillator. An
appropriate implantable cardioverter-defibrillator dis-
charge during a mean follow-up of 48 months was re-
corded in 43% of patients. Primo et al.25 report on the
occurrence of cardiac events during follow-up in 13 pa-
tients with hypertrophic cardiomyopathy who received an
implantable cardioverter-defibrillator because of aborted
sudden death (n = 10) or sustained ventricular tachycar-
dia (n = 3). The results were compared with those in 215
patients with an implantable cardioverter-defibrillator and
other structural heart diseases or idiopathic ventricular
fibrillation. After a mean follow-up period of 26 months,
only two of 13 patients received appropriate shocks. At
40 months, the calculated cumulative incidence of shocks
was 21% in patients with hypertrophic cardiomyopathy
and 66% in the rest of patients. No lethal outcome was
recorded in patients with hypertrophic cardiomyopathy,
however, 11 of them were medicamentously treated. The
authors conclude that the implantable cardioverter-
defibrillators have a less important impact on the prog-
nosis in patients with cardiomyopathy than in those with
other etiologies of aborted sudden death.
Recently, Maron et al.26 investigated the efficacy of
cardioverter-defibrillator in 128 patients with hyper-
trophic cardiomyopathy, mean age 40 years. In 43 patients,
defibrillators were implanted for secondary prevention af-
ter either resuscitation from cardiac arrest (with docu-
mented ventricular fibrillation) or sustained ventricular
tachycardia. In the remaining 85 patients, defibrillators
were implanted as a prophylaxis for primary prevention
of sudden cardiac death. The main clinical reasons for
these implantations, either alone or in combination, were
syncope (n = 41), family history of one or more sudden
deaths due to hypertrophic cardiomyopathy (n = 39),
nonsustained ventricular tachycardia on Holter monitor-
ing (n = 32), and left-ventricular wall thickness of at least
30 mm (n = 10). In addition, 56 patients had inducible
ventricular tachycardia or fibrillation on electrophysiologi-
cal testing. Appropriate defibrillator discharge was re-
corded in 29 (23%) of 128 patients during a mean follow-
up period of 3 years. In each of 21 patients with stored
electrocardiography records, ventricular tachycardia or fi-
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brillation was the rhythm that activated the device. Dis-
charges were most frequent (about 11% per year) in the
patients who received defibrillators for secondary preven-
tion. In this group, the device failed to prevent death in
two patients who had end-stage hypertrophic cardiomy-
opathy with severe systolic dysfunction and heart failure.
The rate of appropriate discharge was about 5% per year
in the group of patients who had received defibrillators
solely for primary prevention. Data from this study sup-
port the view that implantable defibrillator can be life-
saving in patients with hypertrophic cardiomyopathy, sup-
porting its use for both secondary and primary prevention.
The decision to implant a cardioverter-defibrillator is
quite clear for patients who had cardiac arrest, symptom-
atic sustained ventricular tachycardia, or sustained ven-
tricular tachyarrhythmia induced during electrophysi-
ological testing (Fig. 1). Does the current evidence justify
implantation of these devices for primary prevention in
high risk patients, many of them young people? The ques-
tion could only be definitely answered by an appropriately
designed, randomized trail of defibrillator versus amio-
darone, however, it would be difficult to conduct because
of ethical considerations, relatively low prevalence of the
disease, and relatively low rate of events.
The Role of Myectomy
In a prospective study by Borggreffe et al.27, ten car-
diac arrest survivors underwent myectomy for hyper-
trophic obstructive cardiomyopathy. Eight of ten patients
had inducible sustained ventricular tachycardia or fibril-
lation before the operation. After myectomy, ventricular
tachycardia was rendered noninducible in all ten patients
by use of an aggressive protocol stimulation with up to
three extrastimuli. During a mean follow-up of 4.5 years,
no ventricular tachyarrhythmias occurred in any of these
patients.This preliminary observation could be explained
by surgical removal of the arrhythmogenic substrate, and
may support a potential mechanism of the beneficial long-
term postoperative results. Therefore, in some patients
with cardiac arrest and inducible ventricular tachyarrhyt-
hmias, myectomy may be the treatment of choice, because
it represents a curative approach for these arrhythmias.
Fig. 1. Stored ventricular electrogram of a patient with hypertrophic cardiomyopathy who received a cardioverter-defibrillator because of
syncope and inducible sustained ventricular tachycardia. On physical activity (length of sinus cycle, 460 ms; upper panel), fast ventricular
tachycardia occurred with a mean cycle length of 260 ms. The device records ventricular tachycardia, discharges shock (CD), and restores
sinus rhythm (lower panel).
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Recommendations
The treatment of patients with hypertrophic cardi-
omyopathy and ventricular tachyarrhythmias depends on
the clinical presentation, type of cardiomyopathy (obstruc-
tive or nonobstructive), age, and risk level. Patients who
have survived cardiac arrest or have sustained ventricular
tachycardia without any evident precipitating cause that
can be eliminated, have an indication for implantable
cardioverter-defibrillator. In some cases with hypertrophic
obstructive cardiomyopathy and such ventricular tachy-
arrhythmias, myectomy with pre- and postoperative elec-
trophysiological testing may be performed, however, it can
only be done at highly specialized cardiosurgical centers.
The patients with symptoms of impaired consciousness
and nonsustained ventricular tachycardia are candidates
for programmed ventricular stimulation (Fig. 2). Patients
with inducible sustained ventricular tachycardia or fibril-
lation have an indication for implantable cardioverter-
defibrillator, while those with noninducible ventricular
tachyarrhythmias may be treated by amiodarone.
Asymptomatic patients with nonsustained ventricular
tachycardia should not be prophylactically treated with
amiodarone, because their prognosis does not differ from
the prognosis of asymptomatic patients without nonsu-
stained ventricular tachycardia. However, asymptomatic
patients who have two or more risk factors for sudden
Fig. 2. Our algorithm for the management of patients with hyper-
trophic cardiomyopathy and nonsustained ventricular tachycardia.
PVS = programmed ventricular stimulation; VT = ventricular ta-
chycardia; VF = ventricular fibrillation.
cardiac death are also candidates for programmed ven-
tricular stimulation with subsequent pharmacological or
nonpharmacological treatment. Genetic testing may be
especially important to determine therapy in this group of
patients. Early identification of hypertrophic cardiomy-
opathy and subsequent discontinuation of competitive,
high- and medium-grade physical activity are mandatory
in competitive athletes or other asymptomatic or mildly
symptomatic young patients, because these measures re-
sult in a substantial reduction in the risk of sudden car-
diac death in these individuals.
Conclusion
The low prevalence of hypertrophic cardiomyopathy,
low incidence of sudden cardiac death among affected pa-
tients, and different potential causes of death make it dif-
ficult to provide evidence-based criteria for effective pre-
vention of sudden cardiac death in an individual case. In
high risk patients, curative or palliative therapy should be
directed toward elimination or treatment of the precipi-
tating cause. In these patients with proved ventricular elec-
tric vulnerability due to an arrhythmogenic substrate, an
implantable cardioverter-defibrillator is indicated. The
value of these devices in primary prevention has yet to be
established in the future.
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Saæetak
HIPERTROFI»NA KARDIOMIOPATIJA: KAKO LIJE»ITI RIZI»NE BOLESNIKE?
D. PetraË
HipertrofiËna kardiomiopatija je primarna bolest srËanog mi¹iÊa, Ëije kliniËko oËitovanje varira od benignog, asimptomatskog
tijeka do te¹ke srËane dekompenzacije ili srËanog aresta. Stoga je otkrivanje pojedinaËnog rizika od nagle srËane smrti prvi
korak u lijeËenju bolesnika s hipertrofiËnom kardiomiopatijom. »imbenici koji najbolje otkrivaju visoko riziËne bolesnike su
srËani arest ili sinkopa u povijesti, moguÊnost izazivanja postojane ventrikulske tahiaritmije, prisutnost nepostojane ventrikulske
tahikardije u simptomatskih bolesnika, ishemija povezana s hipotenzijom u djece, te prisutnost mutacija te¹kog lanca beta-
miozina zajedno s obiteljskom povije¹Êu nagle srËane smrti. LijeËenje bolesnika s hipertrofiËnom kardiomiopatijom ovisi o
simptomima i visini rizika. Bolesnici s preæivjelim srËanim arestom ili postojanom ventrikulskom tahikardijom, te bolesnici s
izazvanom postojanom ventrikulskom tahiaritmijom tijekom programirane stimulacije ventrikla imaju indikaciju za ugradnju
kardioverter-defibrilatora. U bolesnika s poremeÊajem svijesti i nepostojanom ventrikulskom tahikardijom bez moguÊnosti
izazivanja ventrikulskih tahiaritmija dolazi u obzir lijeËenje amjodaronom. Asimptomatski bolesnici s nepostojanom ventrikulskom
tahikardijom ne trebaju profilaktiËnu terapiju lijekovima, jer je njihova prognoza jednaka kao i prognoza asimptomatskih
bolesnika bez takve tahikardije. Asimptomatski bolesnici s dva ili tri riziËna Ëimbenika kandidati su za programiranu ventrikulsku
stimulaciju i susljedno farmakolo¹ko ili nefarmakolo¹ko lijeËenje. S druge strane, asimptomatski bolesnici bez riziËnih Ëimbenika
imaju dobru prognozu i treba ih pustiti da vode normalan æivot. Meðutim, u mladih asimptomatskih bolesnika ili ¹porta¹a
treba ukinuti natjecateljske, te¹ke i srednje te¹ke tjelesne aktivnosti, jer se na taj naËin znatno smanjuje njihov rizik od nagle
srËane smrti.
KljuËne rijeËi: Kardiomiopatija, hipertrofiËna, komplikacije; Kardiomiopatija, hipertrofiËna, terapija; Smrt, nagla, srËana; Ëimbenici
rizika
